Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Employees

Sector

Pharmaceuticals

Calendar

08-13 - Earnings release - Q1 2027

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	JP¥4,805.00	+4.00%	112,400
09/07/26	JP¥4,620.00	+1.32%	109,100
08/07/26	JP¥4,560.00	-1.72%	109,000
07/07/26	JP¥4,640.00	-4.13%	136,600
06/07/26	JP¥4,840.00	+3.97%	216,800

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 07:30:00 10/07/2026 BST			5-day change	1st Jan Change
4,805.00 ^JPY	+4.00%		+3.22%	-20.32%

02-20	Japan Panel Clears First iPS Cell Therapies for Conditional Sale	MT
02-19	Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's	RE

Market Cap	39.68B 246M 215M 198M 183M 347M 23.43B 353M 2.37B 930M 11.54B 922M 902M	P/E 2025	-103x	P/E 2026	-56.3x
Enterprise Value	35.78B 222M 194M 179M 165M 313M 21.13B 318M 2.14B 839M 10.41B 832M 814M	EV / Sales 2025	356x	EV / Sales 2026	255x
Free-Float	73.74%	Yield 2025 *	-	Yield 2026	-

02-20	Japan Panel Clears First iPS Cell Therapies for Conditional Sale	MT
02-19	Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's	RE
02-19	Japan government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's, newspaper says	RE
02-04	Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up	MT
22/09/24	Cuorips Inc.(TSE:4894) added to S&P Global BMI Index	CI
22/12/23	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
23/09/23	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	CI
27/06/23	Cuorips Inc. has completed an IPO in the amount of Â¥3.432 billion.	CI

02-19	UPDATE2: Japan gov't panel approves 2 iPS-derived drugs in global first	AQ
02-19	UPDATE1: Japan gov't panel approves 2 iPS-derived drugs in global first	AQ
02-19	Japan gov't panel approves 2 iPS-derived drugs in global first	AQ

Cuorips Inc. Share Price

Stocks

4894

JP3266030000

Pharmaceuticals

Valuation: Cuorips Inc.

Chart: Cuorips Inc.

Latest news : Cuorips Inc.

Press Releases: Cuorips Inc.

News in other languages: Cuorips Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cuorips Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+4.00%
1 week	+3.22%
Current month	+11.10%
1 month	+19.68%
3 months	-31.55%
6 months	-33.63%
Current year	-20.32%

1 week	4,360	4,965
1 month	3,650	4,965
Current year	3,610	12,400
1 year	3,610	12,400
3 years	1,443	12,400
5 years	1,287	12,400
10 years	1,287	12,400

Manager	Title	Age	Since
Takayuki Kusanagi CEO	Chief Executive Officer	67	31/05/2020
Yoshiki Sawa CTO	Chief Tech/Sci/R&D Officer	71	31/07/2021
Tanamura Tadayuki IRC	Investor Relations Contact	44	31/03/2024

Director	Title	Age	Since
Takayuki Kusanagi BRD	Director/Board Member	67	31/07/2020
Yoshiki Sawa BRD	Director/Board Member	71	31/07/2021
Tadashi Samejima BRD	Director/Board Member	66	31/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CUORIPS INC.	+4.00%	+3.22%	-22.12%	+111.12%	246M
REGENERON PHARMACEUTICALS, INC.	-0.51%	+1.57%	+18.72%	-5.52%	67.61B
UCB	-5.16%	-8.63%	+37.37%	+202.27%	51.6B
SAMSUNG BIOLOGICS CO.,LTD.	+5.28%	+39.50%	+39.50%	+39.50%	43B
CSL LIMITED	-2.10%	+0.89%	-49.30%	-53.47%	40.94B
BIOGEN INC.	+0.12%	-7.85%	+47.16%	-29.27%	29.4B
MODERNA, INC.	-10.83%	-14.41%	+99.15%	-44.54%	27.09B
INCYTE CORPORATION	-1.53%	-0.13%	+65.92%	+88.58%	23.32B
INNOVENT BIOLOGICS, INC.	+3.88%	+2.16%	+11.78%	+201.51%	19.89B
SWEDISH ORPHAN BIOVITRUM AB	-1.59%	-1.63%	+61.04%	+130.75%	16.91B
Average	-0.84%	-2.40%	+30.92%	+64.09%	32B
Weighted average by Cap.	-1.36%	-2.83%	+30.45%	+49.43%

	2025	2026
Net sales	175M 1.08M 948K 874K 807K 1.53M 103M 1.56M 10.44M 4.1M 50.9M 4.07M 3.98M	212M 1.31M 1.15M 1.06M 978K 1.86M 125M 1.89M 12.65M 4.97M 61.67M 4.93M 4.82M
Net income	-644M -3.99M -3.49M -3.22M -2.97M -5.64M -380M -5.73M -38.43M -15.09M -187M -14.97M -14.64M	-1.02B -6.33M -5.53M -5.1M -4.71M -8.95M -603M -9.1M -60.99M -23.95M -297M -23.76M -23.24M
Net Debt	-4.79B -29.67M -25.96M -23.94M -22.11M -41.96M -2.83B -42.66M -286M -112M -1.39B -111M -109M	-3.9B -24.14M -21.11M -19.48M -17.99M -34.13M -2.3B -34.7M -233M -91.38M -1.13B -90.64M -88.66M